Public Assessment Report. Decentralised Procedure

Public Assessment Report Decentralised Procedure NEOVENT TM /SEREFLO TM CFC-FREE INHALER 25 MICROGRAMS PER ACTUATION PRESSURISED INHALATION SUSPENSION (salmeterol xinafoate) UK Licence No: PL 08137/0272 and 5 NEOLAB LIMITED

LAY SUMMARY On 12 th April 2011, the UK granted Marketing Authorisations (licences) for Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension to Neolab Limited Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension contain the drug salmeterol. Salmeterol belongs to a group of medicines called selective long-acting inhaled β 2 adrenoceptor agonists and is a long-acting bronchodilator. It helps the airways in the lungs to stay open. This makes it easier for air to get in and out. The effects of salmeterol usually last for at least 12 hours. When taken regularly, Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension will help to prevent: Breathing problems caused by asthma including asthma brought on by exercise and asthma at night in adults and adolescents over 12 years of age and Breathing problems caused by other chest diseases known as chronic obstructive pulmonary disease or COPD or chronic bronchitis in adults. Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension helps to prevent breathlessness and wheezing coming on; however it should not be used to treat acute severe asthma symptoms or asthma that is getting worse or deteriorating. When used in the treatment and management of asthma Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension is used as add-on treatment to corticosteroids (also known simply as steroids) when corticosteroids are not providing adequate control when administered alone. Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension must only be prescribed to patients with asthmas who are already taking inhaled corticosteroids or/and oral corticotheroids. Its use is complementary to corticosteroids and patients with asthma must be warned not to stop their treatment with corticosteroids and not to reduce them even if they feel considerably better, without seeking advice from their general practitioner or their asthma consultant. Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension must not be used as the first treatment for asthma, it is not a replacement for oral or inhaled corticosteroids. When used in the treatment and management of asthma Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension can be prescribed for adults and adolescents over the age of 12 years but must NOT be prescribed for children 12 years of age and younger. The safety and efficacy of Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension have not been demonstrated in this young age group. 2

Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension should be used with a Volumatic spacing device by patients who find it difficult to synchronise actuation of the inhaler with breathing in. This is particularly seen in the elderly population. No new or unexpected safety concerns arose from these applications. It was judged that the benefits of taking Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension outweigh the risks; hence Marketing Authorisations have been granted. 3

TABLE OF CONTENTS Module 1: Information about initial procedure Page 5 Module 2: Summary of Product Characteristics Neovent Page 6 Sereflow Page 15 Module 3: Product Information Leaflet Neovent Page 24 Sereflow Page 28 Module 4: Labelling Neovent Page 30 Sereflow Page 32 Module 5: Scientific Discussion Page 33 1 Introduction 2 Quality aspects 3 Non-clinical aspects 4 Clinical aspects 5 Overall conclusions Module 6: Steps taken after initial procedure Page 53 4

Module 1 Product Name Type of Application Active Substance Form Strength MA Holder Reference Member State (RMS) CMS Procedure Number Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension Directive 2001/83/EC, Article 10.3 hybrid application Salmeterol xinafoate pressurised inhalation, suspension 25 micrograms Neolab Limited 57 High Street Odiham HANTS RG29 1LF U.K. UK UK/H/3624/001/DC: Germany (DE), Ireland (IE), the Netherlands (NL) and Poland (PL) UK/H/3625/001/DC: Germany (DE) End of Procedure Day 210 9 th February 2011 5

Module 2 Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Neovent TM CFC-free Inhaler 25 micrograms per 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose (ex-valve) contains 25 micrograms salmeterol (as xinafoate). This is equivalent to a delivered dose (ex-actuator) of 21 micrograms salmeterol (as xinafoate). Excipient(s): For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Pressurised inhalation, suspension. Pressurised aluminium canister containing a white suspension sealed with a metering valve, with a mid-green polypropylene actuator and a pale green polypropylene dust cap. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Regular symptomatic add-on treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma, who are inadequately controlled on inhaled corticosteroids in accordance with current treatment guidelines. Treatment of chronic obstructive pulmonary disease (COPD). Prevention of exercise-induced asthma. 4.2 Posology and method of administration For inhalation use. Neovent TM CFC-free Inhaler 25 micrograms should be used regularly. The full benefits of treatment will be apparent after several doses of the medicinal product. As there may be adverse reactions associated with excessive dosing with this class of medicinal product, the dosage or frequency of administration should only be increased on medical advice. Recommended Doses: Asthma Adults and adolescents over 12 years of age: Two actuations of 25 micrograms salmeterol twice daily. In asthma patients with more severe airways obstruction up to four inhalations of 25 micrograms of salmeterol twice daily may be of benefit. Children: The safety and efficacy of Neovent TM CFC-free Inhaler 25 micrograms have not been demonstrated in children. Therefore Neovent TM CFC-free Inhaler 25 micrograms should not be used in children 12 years of age and younger. COPD Adults: Two actuations of 25 micrograms salmeterol twice daily. Children: There is no relevant indication for use of Neovent TM CFC-free Inhaler 25 micrograms in children. Special patient groups: There is no need to adjust the dose in elderly patients or in those with renal impairment. There are no data available on the use of salmeterol in patients with hepatic impairment. 6

INSTRUCTIONS FOR USE: Patients should be carefully instructed in the proper use of their inhaler (see Patient Information Leaflet). 1. Patients should remove the mouthpiece cover by gently squeezing the sides of the cover and check the mouthpiece inside and outside to see that it is clean. 2. Patients should shake the inhaler well, before use. 3. Before using for the first time patients should release two actuations into the air to make sure that it works. After cleaning or if the inhaler has not been used for a week patients should release one actuation into the air. 4. In a sitting or standing position, patients should hold the inhaler upright between fingers and thumb with their thumb on the base, below the mouthpiece. 5. Patients should breathe out as far as is comfortable and then place the mouthpiece in their mouth between their teeth and close their lips around it. Patients should be instructed not to bite the mouthpiece. 6. Just after starting to breathe in through their mouth patients should press down on the top of the inhaler to release salmeterol while still breathing in steadily and deeply. 7. While holding their breath, patients should take the inhaler from their mouth and take their finger from the top of the inhaler. They should continue holding their breath for as long as is comfortable. 8. If patients are going to take a further actuation, they should keep the inhaler upright and wait about half a minute before repeating steps 2 to 7. 9. After use patients should always replace the mouthpiece cover to keep out dust and fluff. The mouthpiece cover is replaced by firmly pushing and snapping the cap into position. Important: Patients should not rush stages 5, 6 and 7. It is important that they start to breathe in as slowly as possible just before operating their inhaler. Patients should practise in front of a mirror for the first few times. If they see mist coming from the top of their inhaler or the sides of the mouth they should start again from stage 2. People with weak hands may find it easier to hold the inhaler with both hands. Put the two forefingers on top of the inhaler and both thumbs on the base below the mouthpiece. Neovent TM CFC-free Inhaler 25 micrograms should be used with a Volumatic spacer device by patients who find it difficult to synchronise aerosol actuation with inspiration of breath, which is often the case for the elderly. The patient should be referred to the Volumatic instruction leaflet provided with the spacer device, for full details on its correct use. If their inhaler has been exposed to low temperatures, the patient should take the metal canister out of the plastic case and warm it in their hands for a few minutes. Following warming, one actuation should be released into the air prior to use. Cleaning the inhaler: The inhaler should be cleaned at least once a week by: 1. Removing the mouthpiece cover. 2. The canister must not be removed from the plastic casing. 3. Wiping the inside and outside of the mouthpiece and the plastic holder with a dry cloth or tissue. 7

4. Firing one spray to waste before next use. 5. Replacing the mouthpiece cover. PATIENTS MUST NOT PUT THE METAL CANISTER INTO WATER. 4.3 Contraindications Neovent TM CFC-free Inhaler 25 micrograms is contraindicated in patients with hypersensitivity to salmeterol xinafoate or to any of the excipients (See Section 6.1). Neovent TM CFC-free Inhaler 25 micrograms contains soya lecithin and is contraindicated in patients who have peanut or soya allergies. 4.4 Special warnings and precautions for use The management of asthma should normally follow a stepwise programme and patient response should be monitored clinically and by lung function tests. Salmeterol should not be used (and is not sufficient) as the first treatment for asthma. Salmeterol is not a replacement for oral or inhaled corticosteroids. Its use is complementary to them. Patients must be warned not to stop steroid therapy and not to reduce it without medical advice even if they feel better on salmeterol. Salmeterol should not be used to treat acute asthma symptoms for which a fast and short-acting inhaled bronchodilator is required. Patients should be advised to have their medicinal product to be used for the relief of acute asthma symptoms available at all times. Increasing use of short-acting bronchodilators to relieve asthma symptoms indicates deterioration of asthma control. The patient should be instructed to seek medical advice if short-acting relief bronchodilator treatment becomes less effective or more inhalations than usual are required. In this situation the patient should be assessed and consideration given to the need for increased antiinflammatory therapy (e.g. higher doses of inhaled corticosteroid or a course of oral corticosteroid). Severe exacerbations of asthma must be treated in the normal way. Although salmeterol may be introduced as add-on therapy when inhaled corticosteroids do not provide adequate control of asthma symptoms, patients should not be initiated on salmeterol during an acute severe asthma exacerbation, or if they have significantly worsening or acutely deteriorating asthma. Serious asthma-related adverse events and exacerbations may occur during treatment with salmeterol. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation on salmeterol. Sudden and progressive deterioration in control of asthma is potentially life-threatening and the patient should undergo urgent medical assessment. Consideration should be given to increasing corticosteroid therapy. Under these circumstances daily peak flow monitoring may be advisable. For maintenance treatment of asthma salmeterol should be given in combination with inhaled or oral corticosteroids. Long-acting bronchodilators should not be the only or the main treatment in maintenance asthma therapy (see Section 4.1). Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of salmeterol. Regular review of patients as treatment is stepped down is important. The lowest effective dose of salmeterol should be used. As with other inhalational therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing and fall in expiratory flow rate (PEFR) after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. Salmeterol therapy should be discontinued immediately, the patient assessed, and if necessary alternative therapy instituted. Salmeterol should be administered with caution in patients with thyrotoxicosis. There have been very rare reports of increases in blood glucose levels (see section 4.8) and this should be considered when prescribing to patients with a history of diabetes mellitus. 8

Cardiovascular effects such as increases in systolic blood pressure and heart rate may occasionally be seen with all sympathomimetic drugs, especially at higher than therapeutic doses. For this reason, salmeterol should be used with caution in patients with pre-existing cardiovascular disease. Potentially serious hypokalaemia may result from β 2 agonist therapy. Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. Data from a large clinical trial (the Salmeterol Multi-Center Asthma Research Trial, SMART) suggested African-American patients were at increased risk of serious respiratory-related events or deaths when using salmeterol compared with placebo (see section 5.1). It is not known if this was due to pharmacogenetic or other factors. Patients of black African or Afro-Caribbean ancestry should therefore be asked to continue treatment but to seek medical advice if asthma symptoms remained uncontrolled or worsen whilst using salmeterol. Concomitant use of systemic ketoconazole significantly increases systemic exposure to salmeterol. This may lead to an increase in the incidence of systemic effects (e.g. prolongation in the QTc interval and palpitations). Concomitant treatment with ketoconazole or other potent CYP3A4 inhibitors should therefore be avoided unless the benefits outweigh the potentially increased risk of systemic side effects of salmeterol treatment (see section 4.5). Patients should be instructed in the proper use of their inhaler and their technique checked to ensure optimum delivery of the inhaled medicinal drug to the lungs. As systemic absorption is largely through the lungs, the use of a spacer plus metered dose inhaler may vary the delivery to the lungs. It should be noted that this could potentially lead to an increase in the risk of systemic adverse effects so that dose adjustment may be necessary. However, a pharmacokinetic study has been undertaken comparing Neovent TM CFC-free Inhaler 25 micrograms and another marketed salmeterol CFC-free pressurised metered dose inhaler each delivered through the Volumatic spacer device. The results confirm comparable systemic and pulmonary absorption for both products. 4.5 Interaction with other medicinal products and other forms of interaction Beta adrenergic blockers may weaken or antagonise the effect of salmeterol. Both non-selective and selective β blockers should be avoided in patients with asthma unless there are compelling reasons for their use. Potentially serious hypokalaemia may result from β 2 agonist therapy. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids and diuretics. Potent CYP3A4 inhibitors Co-administration of ketoconazole (400 mg orally once daily) and salmeterol (50 µg inhaled twice daily) in 15 healthy subjects for 7 days resulted in a significant increase in plasma salmeterol exposure (1.4-fold Cmax and 15-fold AUC). This may lead to an increase in the incidence of other systemic effects of salmeterol treatment (e.g. prolongation of QTc interval and palpitations) compared with salmeterol or ketoconazole treatment alone (see Section 4.4). Clinically significant effects were not seen on blood pressure, heart rate, blood glucose and blood potassium levels. Co-administration with ketoconazole did not increase the elimination half-life of salmeterol or increase salmeterol accumulation with repeat dosing. The concomitant administration of ketoconazole should be avoided, unless the benefits outweigh the potentially increased risk of systemic side effects of salmeterol treatment. There is likely to be a similar risk of interaction with other potent CYP3A4 inhibitors (e.g. itraconazole, telithromycin, ritonavir). Moderate CYP 3A4 inhibitors Co-administration of erythromycin (500mg orally three times a day) and salmeterol (50 µg inhaled twice daily) in 15 healthy subjects for 6 days resulted in a small but non-statistically significant 9

increase in salmeterol exposure (1.4 fold Cmax and 1.2-fold AUC). Co-administration with erythromycin was not associated with any serious adverse effects. 4.6 Pregnancy and lactation There are limited data (less than 300 pregnancy outcomes) from the use of salmeterol in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity with the exception of evidence of some harmful effects on the fetus at very high dose levels (see section 5.3). As a precautionary measure, it is preferable to avoid the use of salmeterol during pregnancy. Available pharmacodynamic/toxicological data in animals have shown excretion of salmeterol in milk. A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from salmeterol therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. Studies of HFA 134a revealed no effects on the reproductive performance and lactation of adult or two successive generations of rats or on the fetal development of rats or rabbits. 4.7 Effects on ability to drive and use machines Based on the pharmacodynamic profile of salmeterol and reported adverse effects there is no or negligible influence of salmeterol on the ability to drive and use machines. 4.8 Undesirable effects Adverse effects are listed below by system organ class and frequency. Frequencies are defined as: very common ( 1/10), common ( 1/100 and < 1/10), uncommon ( 1/1000 and < 1/100), rare ( 1/10,000 and < 1/1000) and very rare (< 1/10,000) including isolated reports. Common and uncommon events were generally determined from clinical trial data. The incidence on placebo was not taken into account. Very rare events are generally determined from post-marketing spontaneous data. The following frequencies are estimated at the standard dose of 50 µg twice daily. Frequencies at the higher dose of 100 µg twice daily have also been taken to account where appropriate. Immune system disorders: Hypersensitivity reactions: Uncommon: rash (itching and redness) Very rare: anaphylactic reactions including oedema and angioedema, bronchospasm and anaphylactic shock Metabolism and nutrition disorders: Rare: hypokalaemia Very rare: hyperglycaemia Psychiatric disorders: Uncommon: nervousness Rare: insomnia Nervous system disorders: Common: tremor and headache Rare: dizziness Cardiac disorders: Common: palpitations Uncommon: tachycardia 10

Very rare: extrasystoles) cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and Respiratory, thoracic and mediastinal disorders: Very rare: oropharyngeal irritation and paradoxical bronchospasm Gastrointestinal disorders: Very rare: nausea Musculoskeletal, connective tissue and bone disorders: Common: muscle cramps Very rare: arthralgia General disorders and administration site conditions: Very rare: non-specific chest pain The pharmacological side effects of β 2 agonist treatment, such as tremor, headache and palpitations have been reported, but tend to be transient and to reduce with regular therapy. Tremor and tachycardia occur more commonly when administered at doses higher than 50 µg twice daily. As with other inhalational therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing and fall in expiratory flow rate (PEFR) after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. Salmeterol therapy should be discontinued immediately, the patient assessed, and if necessary alternative therapy instituted (see section 4.4). 4.9 Overdose The signs and symptoms of a salmeterol overdose are dizziness, increases in systolic blood pressure, tremor, headache and tachycardia. The preferred antidotes are cardioselective β blocking agents, which should be used with extreme caution in patients with a history of bronchospasm. Additionally, hypokalaemia can occur and therefore serum potassium levels should be monitored. Potassium replacement should be considered. 5 PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Selective β 2 adrenoceptor agonists ATC code: R03AC12 Salmeterol is a selective long-acting (12 hour) β 2 adrenoceptor agonist with a long side chain which binds to the exo-site of the receptor. These pharmacological properties of salmeterol offer more effective protection against histamineinduced bronchoconstriction and produce a longer duration of bronchodilation, lasting for at least 12 hours, than recommended doses of conventional short-acting β 2 agonists. In man salmeterol inhibits the early and late phase response to inhaled allergen; the latter persisting for over 30 hours after a single dose when the bronchodilator effect is no longer evident. Single dosing with salmeterol attenuates bronchial hyper-responsiveness. These properties indicate that salmeterol has additional nonbronchodilator activity, but the full clinical significance is not yet clear. The mechanism is different from the anti-inflammatory effect of corticosteroids which should not be stopped or reduced when salmeterol is prescribed. Salmeterol has been studied in the treatment of conditions associated with COPD, and has been shown to improve symptoms, pulmonary function and quality of life. Asthma Clinical Trials The Salmeterol Multi-center Asthma Research Trial (SMART) SMART was a multi-centre, randomised, double blind, placebo-controlled, parallel group 28-week study in the US which randomised 13,176 patients to salmeterol (50 µg twice daily) and 13,179 patients to placebo in addition to the patients usual asthma therapy. Patients were enrolled if 12 years of age, with asthma and if currently using asthma medication (but not a long-acting β 2 agonist). Baseline inhaled corticosteroid use at study entry was recorded, but not required in the study. The 11

primary endpoint in SMART was the combined number of respiratory-related deaths and respiratoryrelated life-threatening experiences. Key findings from SMART: primary endpoint Patient group Number of primary endpoint events /number of patients Relative Risk (95% confidence salmeterol placebo intervals) All patients 50/13176 36/13179 1.40 (0.91, 2.14) Patients using inhaled 23/6127 19/6138 1.21 (0.66, 2.23) corticosteroids Patients not using inhaled 27/7049 17/7041 1.60 (0.87, 2.93) corticosteroids African-American patients 20/2,366 5/2,319 4.10 (1.54, 10.90) (Risk in bold is statistically significant at the 95% level.) Key findings from SMART by inhaled steroid use at baseline: secondary endpoints Number of secondary endpoint events /number of patients Relative Risk (95% confidence salmeterol placebo intervals) Respiratory -related death Patients using inhaled 10/6127 5/6138 2.01 (0.69, 5.86) corticosteroids Patients not using inhaled 14/7049 6/7041 2.28 (0.88, 5.94) corticosteroids Combined asthma-related death or life-threatening experience Patients using inhaled 16/6127 13/6138 1.24 (0.60, 2.58) corticosteroids Patients not using inhaled 21/7049 9/7041 2.39 (1.10, 5.22) corticosteroids Asthma-related death Patients using inhaled 4/6127 3/6138 1.35 (0.30, 6.04) corticosteroids Patients not using inhaled corticosteroids 9/7049 0/7041 * (*=could not be calculated because of no events in placebo group). Risk in bold figures is statistically significant at the 95% level. The secondary endpoints in the table above reached statistical significance in the whole population.) The secondary endpoints of combined all-cause death or life-threatening experience, all cause death or all cause hospitalisation did not reach statistical significance in the whole population. COPD clinical trials TORCH study TORCH was a 3-year study to assess the effect of treatment with a salmeterol/fluticasone propionate dry powder (SFP) 50/500 µg combination bd, salmeterol dry powder 50 µg bd, fluticasone propionate (FP) dry powder 500 µg bd or placebo on all-cause mortality in patients with COPD. COPD patients with a baseline (pre-bronchodilator) FEV1 <60% of predicted normal were randomised to double blind medication. During the study, patients were permitted usual COPD therapy with the exception of other inhaled corticosteroids, long-acting bronchodilators and long-term systemic corticosteroids. Survival status at 3 years was determined for all patients regardless of withdrawal from study medication. The primary endpoint was reduction in all cause mortality at 3 years for SFP vs Placebo. Placebo N = 1524 Salmeterol 50 N = 1521 FP 500 N = 1534 SFP 50/500 N = 1533 All cause mortality at 3 years Number of deaths (%) 231 (15.2%) 205 (13.5%) 246 (16.0%) 193 (12.6%) 12

Hazard Ratio vs Placebo (CIs) p value Hazard Ratio SFP 50/500 vs components (CIs) p value N/A 0.879 (0.73, 1.06) 0.180 N/A 0.932 (0.77, 1.13) 0.481 1.060 (0.89, 1.27) 0.525 0.774 (0.64, 0.93) 0.007 0.825 (0.68, 1.00 ) 0.052 1 1. Non significant P value after adjustment for 2 interim analyses on the primary efficacy comparison from a log-rank analysis stratified by smoking status There was a trend towards improved survival in subjects treated with SFP compared with placebo over 3 years however this did not achieve the statistical significance level p 0.05. The percentage of patients who died within 3 years due to COPD-related causes was 6.0% for placebo, 6.1% for salmeterol, 6.9% for FP and 4.7% for SFP. The mean number of moderate to severe exacerbations per year was significantly reduced with SFP as compared with treatment with salmeterol, FP and placebo (mean rate in the SFP group 0.85 compared with 0.97 in the salmeterol group, 0.93 in the FP group and 1.13 in the placebo). This translates to a reduction in the rate of moderate to severe exacerbations of 25% (95% CI: 19% to 31%; p<0.001) compared with placebo, 12% compared with salmeterol (95% CI: 5% to 19%, p=0.002) and 9% compared with FP (95% CI: 1% to 16%, p=0.024). Salmeterol and FP significantly reduced exacerbation rates compared with placebo by 15% (95% CI: 7% to 22%; p<0.001) and 18% (95% CI: 11% to 24%; p<0.001) respectively. Health Related Quality of Life, as measured by the St George's Respiratory Questionnaire (SGRQ) was improved by all active treatments in comparison with placebo. The average improvement over three years for SFP compared with placebo was -3.1 units (95% CI: -4.1 to -2.1; p<0.001), compared with salmeterol was -2.2 units (p<0.001) and compared with FP was - 1.2 units (p=0.017). A 4-unit decrease is considered clinically relevant. The estimated 3-year probability of having pneumonia reported as an adverse event was 12.3% for placebo, 13.3% for salmeterol, 18.3% for FP and 19.6% for SFP (Hazard ratio for SFP vs placebo: 1.64, 95% CI: 1.33 to 2.01, p<0.001). There was no increase in pneumonia related deaths; deaths while on treatment that were adjudicated as primarily due to pneumonia were 7 for placebo, 9 for salmeterol, 13 for FP and 8 for SFP. There was no significant difference in probability of bone fracture (5.1% placebo, 5.1% salmeterol, 5.4% FP and 6.3% SFP; Hazard ratio for SFP vs placebo: 1.22, 95% CI: 0.87 to 1.72, p=0.248). 5.2 Pharmacokinetic properties Salmeterol acts locally in the lung and previous studies have suggested that plasma levels are not necessarily an indication of therapeutic effects. In addition there are only limited data available on the pharmacokinetics of salmeterol because of the technical difficulty of assaying the active substance in plasma due to the low plasma concentrations at therapeutic doses (approximately 200 picogram/ml or less) achieved after inhaled dosing. 5.3 Preclinical safety data The only findings in animal studies with relevance for clinical use were the effects associated with exaggerated pharmacological activity. In reproduction and developmental toxicity studies with salmeterol xinafoate, there were no effects in rats. In rabbits, typical β 2 agonist embryo fetal toxicity (cleft palate, premature opening of eyelids, sternebral fusion and reduced ossification rate in the frontal cranial bones) occurred at high exposure levels (approximately 20 times the maximum recommended daily dosage for humans, based on the comparison of areas under the curve. Salmeterol xinafoate was negative in a range of standard genotoxicity studies. N/A 13

The non-cfc propellant, norflurane (HFA 134a), has been shown to have no toxic effect at very high vapour concentrations, far in excess of those likely to be experienced by patients, in a wide range of animal species exposed daily for periods of up to two years including no effects on the reproductive performance or embryofetal development. 6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients Anhydrous ethanol Soya lecithin (E322) Norflurane (HFA 134a), a hydrofluoroalkane (non-chlorofluorocarbon) propellant. This product does not contain any chlorofluorocarbon propellants. 6.2 Incompatibilities Not applicable. 6.3 Shelf life 2 years. 6.4 Special precautions for storage Store below 30ºC. Do not freeze. The canister contains a pressurised liquid. Do not expose to temperatures higher than 50ºC. Do not puncture, break or burn even when apparently empty 6.5 Nature and contents of container Pressurised aluminium canister containing a white suspension sealed with a metering valve, with a mid-green polypropylene actuator and a pale green polypropylene dust cap. Each canister provides 120 actuations, each actuation containing 25 micrograms of salmeterol (as xinafoate) corresponding to a delivered dose (ex-actuator) of 21 micrograms salmeterol (as xinafoate). 6.6 Special precautions for disposal No special requirements. Any unused product or waste material should be disposed of in accordance with local requirements. 7 MARKETING AUTHORISATION HOLDER Neolab Limited 57 High Street Odiham HANTS RG29 1LF U.K. 8 MARKETING AUTHORISATION NUMBER(S) PL 08137/0272 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 12/04/2011 10 DATE OF REVISION OF THE TEXT 12/04/2011 14

1 NAME OF THE MEDICINAL PRODUCT Sereflo TM CFC-free Inhaler 25 micrograms per 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose (ex-valve) contains 25 micrograms salmeterol (as xinafoate). This is equivalent to a delivered dose (ex-actuator) of 21 micrograms salmeterol (as xinafoate). Excipient(s): For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Pressurised inhalation, suspension. Pressurised aluminium canister containing a white suspension sealed with a metering valve, with a mid-green polypropylene actuator and a pale green polypropylene dust cap. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Regular symptomatic add-on treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma, who are inadequately controlled on inhaled corticosteroids in accordance with current treatment guidelines. Treatment of chronic obstructive pulmonary disease (COPD). Prevention of exercise-induced asthma. 4.2 Posology and method of administration For inhalation use. Sereflo TM CFC-free Inhaler 25 micrograms should be used regularly. The full benefits of treatment will be apparent after several doses of the medicinal product. As there may be adverse reactions associated with excessive dosing with this class of medicinal product, the dosage or frequency of administration should only be increased on medical advice. Recommended Doses: Asthma Adults and adolescents over 12 years of age: Two actuations of 25 micrograms salmeterol twice daily. In asthma patients with more severe airways obstruction up to four inhalations of 25 micrograms of salmeterol twice daily may be of benefit. Children: The safety and efficacy of Sereflo TM CFC-free Inhaler 25 micrograms have not been demonstrated in children. Therefore Sereflo TM CFC-free Inhaler 25 micrograms should not be used in children 12 years of age and younger. COPD Adults: Two actuations of 25 micrograms salmeterol twice daily. Children: There is no relevant indication for use of Sereflo TM CFC-free Inhaler 25 micrograms in children. Special patient groups: There is no need to adjust the dose in elderly patients or in those with renal impairment. There are no data available on the use of salmeterol in patients with hepatic impairment. INSTRUCTIONS FOR USE: Patients should be carefully instructed in the proper use of their inhaler (see Patient Information Leaflet). 15

1. Patients should remove the mouthpiece cover by gently squeezing the sides of the cover and check the mouthpiece inside and outside to see that it is clean. 2. Patients should shake the inhaler well, before use. 3. Before using for the first time patients should release two actuations into the air to make sure that it works. After cleaning or if the inhaler has not been used for a week patients should release one actuation into the air. 4. In a sitting or standing position, patients should hold the inhaler upright between fingers and thumb with their thumb on the base, below the mouthpiece. 5. Patients should breathe out as far as is comfortable and then place the mouthpiece in their mouth between their teeth and close their lips around it. Patients should be instructed not to bite the mouthpiece. 6. Just after starting to breathe in through their mouth patients should press down on the top of the inhaler to release salmeterol while still breathing in steadily and deeply. 7. While holding their breath, patients should take the inhaler from their mouth and take their finger from the top of the inhaler. They should continue holding their breath for as long as is comfortable. 8. If patients are going to take a further actuation, they should keep the inhaler upright and wait about half a minute before repeating steps 2 to 7. 9. After use patients should always replace the mouthpiece cover to keep out dust and fluff. The mouthpiece cover is replaced by firmly pushing and snapping the cap into position. Important: Patients should not rush stages 5, 6 and 7. It is important that they start to breathe in as slowly as possible just before operating their inhaler. Patients should practise in front of a mirror for the first few times. If they see mist coming from the top of their inhaler or the sides of the mouth they should start again from stage 2. People with weak hands may find it easier to hold the inhaler with both hands. Put the two forefingers on top of the inhaler and both thumbs on the base below the mouthpiece. Sereflo TM CFC-free Inhaler 25 micrograms should be used with a Volumatic spacer device by patients who find it difficult to synchronise aerosol actuation with inspiration of breath, which is often the case for the elderly. The patient should be referred to the Volumatic instruction leaflet provided with the spacer device, for full details on its correct use. If their inhaler has been exposed to low temperatures, the patient should take the metal canister out of the plastic case and warm it in their hands for a few minutes. Following warming, one actuation should be released into the air prior to use. Cleaning the inhaler: The inhaler should be cleaned at least once a week by: 1. Removing the mouthpiece cover. 2. The canister must not be removed from the plastic casing. 3. Wiping the inside and outside of the mouthpiece and the plastic holder with a dry cloth or tissue. 4. Firing one spray to waste before next use. 5. Replacing the mouthpiece cover. PATIENTS MUST NOT PUT THE METAL CANISTER INTO WATER. 16

4.3 Contraindications Sereflo TM CFC-free Inhaler 25 micrograms is contraindicated in patients with hypersensitivity to salmeterol xinafoate or to any of the excipients (See Section 6.1). Sereflo TM CFC-free Inhaler 25 micrograms contains soya lecithin and is contraindicated in patients who have peanut or soya allergies. 4.4 Special warnings and precautions for use The management of asthma should normally follow a stepwise programme and patient response should be monitored clinically and by lung function tests. Salmeterol should not be used (and is not sufficient) as the first treatment for asthma. Salmeterol is not a replacement for oral or inhaled corticosteroids. Its use is complementary to them. Patients must be warned not to stop steroid therapy and not to reduce it without medical advice even if they feel better on salmeterol. Salmeterol should not be used to treat acute asthma symptoms for which a fast and short-acting inhaled bronchodilator is required. Patients should be advised to have their medicinal product to be used for the relief of acute asthma symptoms available at all times. Increasing use of short-acting bronchodilators to relieve asthma symptoms indicates deterioration of asthma control. The patient should be instructed to seek medical advice if short-acting relief bronchodilator treatment becomes less effective or more inhalations than usual are required. In this situation the patient should be assessed and consideration given to the need for increased antiinflammatory therapy (e.g. higher doses of inhaled corticosteroid or a course of oral corticosteroid). Severe exacerbations of asthma must be treated in the normal way. Although salmeterol may be introduced as add-on therapy when inhaled corticosteroids do not provide adequate control of asthma symptoms, patients should not be initiated on salmeterol during an acute severe asthma exacerbation, or if they have significantly worsening or acutely deteriorating asthma. Serious asthma-related adverse events and exacerbations may occur during treatment with salmeterol. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation on salmeterol. Sudden and progressive deterioration in control of asthma is potentially life-threatening and the patient should undergo urgent medical assessment. Consideration should be given to increasing corticosteroid therapy. Under these circumstances daily peak flow monitoring may be advisable. For maintenance treatment of asthma salmeterol should be given in combination with inhaled or oral corticosteroids. Long-acting bronchodilators should not be the only or the main treatment in maintenance asthma therapy (see Section 4.1). Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of salmeterol. Regular review of patients as treatment is stepped down is important. The lowest effective dose of salmeterol should be used. As with other inhalational therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing and fall in expiratory flow rate (PEFR) after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. Salmeterol therapy should be discontinued immediately, the patient assessed, and if necessary alternative therapy instituted. Salmeterol should be administered with caution in patients with thyrotoxicosis. There have been very rare reports of increases in blood glucose levels (see section 4.8) and this should be considered when prescribing to patients with a history of diabetes mellitus. Cardiovascular effects such as increases in systolic blood pressure and heart rate may occasionally be seen with all sympathomimetic drugs, especially at higher than therapeutic doses. For this reason, salmeterol should be used with caution in patients with pre-existing cardiovascular disease. 17

Potentially serious hypokalaemia may result from β 2 agonist therapy. Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. Data from a large clinical trial (the Salmeterol Multi-Center Asthma Research Trial, SMART) suggested African-American patients were at increased risk of serious respiratory-related events or deaths when using salmeterol compared with placebo (see section 5.1). It is not known if this was due to pharmacogenetic or other factors. Patients of black African or Afro-Caribbean ancestry should therefore be asked to continue treatment but to seek medical advice if asthma symptoms remained uncontrolled or worsen whilst using salmeterol. Concomitant use of systemic ketoconazole significantly increases systemic exposure to salmeterol. This may lead to an increase in the incidence of systemic effects (e.g. prolongation in the QTc interval and palpitations). Concomitant treatment with ketoconazole or other potent CYP3A4 inhibitors should therefore be avoided unless the benefits outweigh the potentially increased risk of systemic side effects of salmeterol treatment (see section 4.5). Patients should be instructed in the proper use of their inhaler and their technique checked to ensure optimum delivery of the inhaled medicinal drug to the lungs. As systemic absorption is largely through the lungs, the use of a spacer plus metered dose inhaler may vary the delivery to the lungs. It should be noted that this could potentially lead to an increase in the risk of systemic adverse effects so that dose adjustment may be necessary. However, a pharmacokinetic study has been undertaken comparing Sereflo TM CFC-free Inhaler 25 micrograms and another marketed salmeterol CFC-free pressurised metered dose inhaler each delivered through the Volumatic spacer device. The results confirm comparable systemic and pulmonary absorption for both products. 4.5 Interaction with other medicinal products and other forms of interaction Beta adrenergic blockers may weaken or antagonise the effect of salmeterol. Both non-selective and selective β blockers should be avoided in patients with asthma unless there are compelling reasons for their use. Potentially serious hypokalaemia may result from β 2 agonist therapy. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids and diuretics. Potent CYP3A4 inhibitors Co-administration of ketoconazole (400 mg orally once daily) and salmeterol (50 µg inhaled twice daily) in 15 healthy subjects for 7 days resulted in a significant increase in plasma salmeterol exposure (1.4-fold Cmax and 15-fold AUC). This may lead to an increase in the incidence of other systemic effects of salmeterol treatment (e.g. prolongation of QTc interval and palpitations) compared with salmeterol or ketoconazole treatment alone (see Section 4.4). Clinically significant effects were not seen on blood pressure, heart rate, blood glucose and blood potassium levels. Co-administration with ketoconazole did not increase the elimination half-life of salmeterol or increase salmeterol accumulation with repeat dosing. The concomitant administration of ketoconazole should be avoided, unless the benefits outweigh the potentially increased risk of systemic side effects of salmeterol treatment. There is likely to be a similar risk of interaction with other potent CYP3A4 inhibitors (e.g. itraconazole, telithromycin, ritonavir). Moderate CYP 3A4 inhibitors Co-administration of erythromycin (500mg orally three times a day) and salmeterol (50 µg inhaled twice daily) in 15 healthy subjects for 6 days resulted in a small but non-statistically significant increase in salmeterol exposure (1.4 fold Cmax and 1.2-fold AUC). Co-administration with erythromycin was not associated with any serious adverse effects. 18

4.6 Pregnancy and lactation There are limited data (less than 300 pregnancy outcomes) from the use of salmeterol in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity with the exception of evidence of some harmful effects on the fetus at very high dose levels (see section 5.3). As a precautionary measure, it is preferable to avoid the use of salmeterol during pregnancy. Available pharmacodynamic/toxicological data in animals have shown excretion of salmeterol in milk. A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from salmeterol therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. Studies of HFA 134a revealed no effects on the reproductive performance and lactation of adult or two successive generations of rats or on the fetal development of rats or rabbits. 4.7 Effects on ability to drive and use machines Based on the pharmacodynamic profile of salmeterol and reported adverse effects there is no or negligible influence of salmeterol on the ability to drive and use machines. 4.8 Undesirable effects Adverse effects are listed below by system organ class and frequency. Frequencies are defined as: very common ( 1/10), common ( 1/100 and < 1/10), uncommon ( 1/1000 and < 1/100), rare ( 1/10,000 and < 1/1000) and very rare (< 1/10,000) including isolated reports. Common and uncommon events were generally determined from clinical trial data. The incidence on placebo was not taken into account. Very rare events are generally determined from post-marketing spontaneous data. The following frequencies are estimated at the standard dose of 50 µg twice daily. Frequencies at the higher dose of 100 µg twice daily have also been taken to account where appropriate. Immune system disorders: Hypersensitivity reactions: Uncommon: rash (itching and redness) Very rare: anaphylactic reactions including oedema and angioedema, bronchospasm and anaphylactic shock Metabolism and nutrition disorders: Rare: hypokalaemia Very rare: hyperglycaemia Psychiatric disorders: Uncommon: nervousness Rare: insomnia Nervous system disorders: Common: tremor and headache Rare: dizziness Cardiac disorders: Common: palpitations Uncommon: tachycardia Very rare: cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles) Respiratory, thoracic and mediastinal disorders: 19

Very rare: oropharyngeal irritation and paradoxical bronchospasm Gastrointestinal disorders: Very rare: nausea Musculoskeletal, connective tissue and bone disorders: Common: muscle cramps Very rare: arthralgia General disorders and administration site conditions: Very rare: non-specific chest pain The pharmacological side effects of β 2 agonist treatment, such as tremor, headache and palpitations have been reported, but tend to be transient and to reduce with regular therapy. Tremor and tachycardia occur more commonly when administered at doses higher than 50 µg twice daily. As with other inhalational therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing and fall in expiratory flow rate (PEFR) after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. Salmeterol therapy should be discontinued immediately, the patient assessed, and if necessary alternative therapy instituted (see section 4.4). 4.9 Overdose The signs and symptoms of a salmeterol overdose are dizziness, increases in systolic blood pressure, tremor, headache and tachycardia. The preferred antidotes are cardioselective β blocking agents, which should be used with extreme caution in patients with a history of bronchospasm. Additionally, hypokalaemia can occur and therefore serum potassium levels should be monitored. Potassium replacement should be considered. 5 PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties Pharmacotherapeutic group: Selective β 2 adrenoceptor agonists ATC code: R03AC12 Salmeterol is a selective long-acting (12 hour) β 2 adrenoceptor agonist with a long side chain which binds to the exo-site of the receptor. These pharmacological properties of salmeterol offer more effective protection against histamineinduced bronchoconstriction and produce a longer duration of bronchodilation, lasting for at least 12 hours, than recommended doses of conventional short-acting β 2 agonists. In man salmeterol inhibits the early and late phase response to inhaled allergen; the latter persisting for over 30 hours after a single dose when the bronchodilator effect is no longer evident. Single dosing with salmeterol attenuates bronchial hyper-responsiveness. These properties indicate that salmeterol has additional nonbronchodilator activity, but the full clinical significance is not yet clear. The mechanism is different from the anti-inflammatory effect of corticosteroids which should not be stopped or reduced when salmeterol is prescribed. Salmeterol has been studied in the treatment of conditions associated with COPD, and has been shown to improve symptoms, pulmonary function and quality of life. Asthma Clinical Trials The Salmeterol Multi-center Asthma Research Trial (SMART) SMART was a multi-centre, randomised, double blind, placebo-controlled, parallel group 28-week study in the US which randomised 13,176 patients to salmeterol (50 µg twice daily) and 13,179 patients to placebo in addition to the patients usual asthma therapy. Patients were enrolled if 12 years of age, with asthma and if currently using asthma medication (but not a long-acting β 2 agonist). Baseline inhaled corticosteroid use at study entry was recorded, but not required in the study. The primary endpoint in SMART was the combined number of respiratory-related deaths and respiratoryrelated life-threatening experiences. Key findings from SMART: primary endpoint 20

Patient group Number of primary endpoint events /number of patients Relative Risk (95% confidence salmeterol placebo intervals) All patients 50/13176 36/13179 1.40 (0.91, 2.14) Patients using inhaled 23/6127 19/6138 1.21 (0.66, 2.23) corticosteroids Patients not using inhaled 27/7049 17/7041 1.60 (0.87, 2.93) corticosteroids African-American patients 20/2,366 5/2,319 4.10 (1.54, 10.90) (Risk in bold is statistically significant at the 95% level.) Key findings from SMART by inhaled steroid use at baseline: secondary endpoints Number of secondary endpoint events /number of patients Relative Risk (95% confidence salmeterol placebo intervals) Respiratory -related death Patients using inhaled 10/6127 5/6138 2.01 (0.69, 5.86) corticosteroids Patients not using inhaled 14/7049 6/7041 2.28 (0.88, 5.94) corticosteroids Combined asthma-related death or life-threatening experience Patients using inhaled 16/6127 13/6138 1.24 (0.60, 2.58) corticosteroids Patients not using inhaled 21/7049 9/7041 2.39 (1.10, 5.22) corticosteroids Asthma-related death Patients using inhaled 4/6127 3/6138 1.35 (0.30, 6.04) corticosteroids Patients not using inhaled corticosteroids 9/7049 0/7041 * (*=could not be calculated because of no events in placebo group). Risk in bold figures is statistically significant at the 95% level. The secondary endpoints in the table above reached statistical significance in the whole population.) The secondary endpoints of combined all-cause death or life-threatening experience, all cause death or all cause hospitalisation did not reach statistical significance in the whole population. COPD clinical trials TORCH study TORCH was a 3-year study to assess the effect of treatment with a salmeterol/fluticasone propionate dry powder (SFP) 50/500 µg combination bd, salmeterol dry powder 50 µg bd, fluticasone propionate (FP) dry powder 500 µg bd or placebo on all-cause mortality in patients with COPD. COPD patients with a baseline (pre-bronchodilator) FEV1 <60% of predicted normal were randomised to double blind medication. During the study, patients were permitted usual COPD therapy with the exception of other inhaled corticosteroids, long-acting bronchodilators and long-term systemic corticosteroids. Survival status at 3 years was determined for all patients regardless of withdrawal from study medication. The primary endpoint was reduction in all cause mortality at 3 years for SFP vs Placebo. All cause mortality at 3 years Placebo N = 1524 Number of deaths (%) 231 (15.2%) Hazard Ratio vs Placebo (CIs) p value Salmeterol 50 N = 1521 205 (13.5%) N/A 0.879 (0.73, 1.06) 0.180 FP 500 N = 1534 246 (16.0%) 1.060 (0.89, 1.27) 0.525 SFP 50/500 N = 1533 193 (12.6%) 0.825 (0.68, 1.00 ) 0.052 1 21

Hazard Ratio SFP 50/500 vs components (CIs) p value N/A 0.932 (0.77, 1.13) 0.481 0.774 (0.64, 0.93) 0.007 1. Non significant P value after adjustment for 2 interim analyses on the primary efficacy comparison from a log-rank analysis stratified by smoking status There was a trend towards improved survival in subjects treated with SFP compared with placebo over 3 years however this did not achieve the statistical significance level p 0.05. The percentage of patients who died within 3 years due to COPD-related causes was 6.0% for placebo, 6.1% for salmeterol, 6.9% for FP and 4.7% for SFP. The mean number of moderate to severe exacerbations per year was significantly reduced with SFP as compared with treatment with salmeterol, FP and placebo (mean rate in the SFP group 0.85 compared with 0.97 in the salmeterol group, 0.93 in the FP group and 1.13 in the placebo). This translates to a reduction in the rate of moderate to severe exacerbations of 25% (95% CI: 19% to 31%; p<0.001) compared with placebo, 12% compared with salmeterol (95% CI: 5% to 19%, p=0.002) and 9% compared with FP (95% CI: 1% to 16%, p=0.024). Salmeterol and FP significantly reduced exacerbation rates compared with placebo by 15% (95% CI: 7% to 22%; p<0.001) and 18% (95% CI: 11% to 24%; p<0.001) respectively. Health Related Quality of Life, as measured by the St George's Respiratory Questionnaire (SGRQ) was improved by all active treatments in comparison with placebo. The average improvement over three years for SFP compared with placebo was -3.1 units (95% CI: -4.1 to -2.1; p<0.001), compared with salmeterol was -2.2 units (p<0.001) and compared with FP was - 1.2 units (p=0.017). A 4-unit decrease is considered clinically relevant. The estimated 3-year probability of having pneumonia reported as an adverse event was 12.3% for placebo, 13.3% for salmeterol, 18.3% for FP and 19.6% for SFP (Hazard ratio for SFP vs placebo: 1.64, 95% CI: 1.33 to 2.01, p<0.001). There was no increase in pneumonia related deaths; deaths while on treatment that were adjudicated as primarily due to pneumonia were 7 for placebo, 9 for salmeterol, 13 for FP and 8 for SFP. There was no significant difference in probability of bone fracture (5.1% placebo, 5.1% salmeterol, 5.4% FP and 6.3% SFP; Hazard ratio for SFP vs placebo: 1.22, 95% CI: 0.87 to 1.72, p=0.248). 5.2 Pharmacokinetic properties Salmeterol acts locally in the lung and previous studies have suggested that plasma levels are not necessarily an indication of therapeutic effects. In addition there are only limited data available on the pharmacokinetics of salmeterol because of the technical difficulty of assaying the active substance in plasma due to the low plasma concentrations at therapeutic doses (approximately 200 picogram/ml or less) achieved after inhaled dosing. 5.3 Preclinical safety data The only findings in animal studies with relevance for clinical use were the effects associated with exaggerated pharmacological activity. In reproduction and developmental toxicity studies with salmeterol xinafoate, there were no effects in rats. In rabbits, typical β 2 agonist embryo fetal toxicity (cleft palate, premature opening of eyelids, sternebral fusion and reduced ossification rate in the frontal cranial bones) occurred at high exposure levels (approximately 20 times the maximum recommended daily dosage for humans, based on the comparison of areas under the curve. Salmeterol xinafoate was negative in a range of standard genotoxicity studies. The non-cfc propellant, norflurane (HFA 134a), has been shown to have no toxic effect at very high vapour concentrations, far in excess of those likely to be experienced by patients, in a wide range of animal species exposed daily for periods of up to two years including no effects on the reproductive performance or embryofetal development. N/A 22

6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients Anhydrous ethanol Soya lecithin (E322) Norflurane (HFA 134a), a hydrofluoroalkane (non-chlorofluorocarbon) propellant. This product does not contain any chlorofluorocarbon propellants. 6.2 Incompatibilities Not applicable. 6.3 Shelf life 2 years. 6.4 Special precautions for storage Store below 30ºC. Do not freeze. The canister contains a pressurised liquid. Do not expose to temperatures higher than 50ºC. Do not puncture, break or burn even when apparently empty 6.5 Nature and contents of container Pressurised aluminium canister containing a white suspension sealed with a metering valve, with a mid-green polypropylene actuator and a pale green polypropylene dust cap. Each canister provides 120 actuations, each actuation containing 25 micrograms of salmeterol (as xinafoate) corresponding to a delivered dose (ex-actuator) of 21 micrograms salmeterol (as xinafoate). 6.6 Special precautions for disposal No special requirements. Any unused product or waste material should be disposed of in accordance with local requirements. 7 MARKETING AUTHORISATION HOLDER Neolab Limited 57 High Street Odiham HANTS RG29 1LF U.K. 8 MARKETING AUTHORISATION NUMBER(S) PL 08137/0275 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 12/04/2011 10 DATE OF REVISION OF THE TEXT 12/04/2011 23

Module 3 Product Information Leaflet 24

25

26

27

28

29

Module 4 Labelling 30

31

32

Module 5 Scientific discussion during initial procedure I INTRODUCTION Based on the review of the data on quality, safety and efficacy, the Reference Member State (the UK) and the Concerned Member States of Germany (DE), Ireland (IE), The Netherlands (NL) and Poland (PL) considered that the application for Neovent TM CFC-free Inhaler 25 micrograms per actuation pressured inhalation, suspension could be approved. The Reference Member State (the UK) and the Concerned Member States of Germany (DE) considered that the duplicate application for Sereflo TM CFC-free Inhaler 25 micrograms per actuation pressured inhalation, suspension could be approved. Neovent TM /Sereflo TM CFC-free Inhaler 25 micrograms per actuation pressured inhalation, suspension are prescription-only medicines (POM). Neovent TM /Sereflo TM CFC-free Inhaler 25 micrograms per actuation pressured inhalation, suspension are indicated for use in adults and adolescents over 12 years of age for the: Regular symptomatic add-on treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma, who are inadequately controlled on inhaled corticosteroids in accordance with current treatment guidelines and Prevention of exercise-induced asthma. They are indicated for use in adults for the: Treatment of chronic obstructive pulmonary disease (COPD). These applications for Neovent TM /Sereflo TM CFC-free Inhaler 25 micrograms per actuation pressured inhalation, suspension are submitted as abridged applications according to Article 10.3 of Directive 2001/83/EC and are hybrid applications applications for medicinal products referring to a so-called reference medicinal product with a Marketing Authorisation in a Member State or in the Community and which is or has been authorised for not less than 6/10 years in the EEA. The reference product for these applications is Serevent 25 micrograms pressurised inhalation suspension, first authorised in Denmark to GlaxoSmithkline Pharma A/S on 25th June 1991. The UK reference product is Serevent Evohaler 25 micrograms per actuation pressurised inhalation suspension, first authorised in the UK to Glaxo Wellcome UK Limited on 12 th December 2005 (PL 10949/0369). No new non-clinical studies were conducted, which is acceptable given that the products contain a widely-used, well-known active substance. Four clinical pharmacology studies were submitted with these applications, three pharmacokinetic studies (one of which was a study using a spacing device) and one pharmacodynamic study, and two clinical studies were submitted. 33

For manufacturing sites within the Community, the RMS has accepted copies of current manufacturer authorisations issued by inspection services of the competent authorities as certification that acceptable standards of GMP are in place at those sites. For manufacturing sites outside the community, the RMS has accepted copies of current GMP Certificates or satisfactory inspection summary reports, close-out letters or exchange of information issued by the inspection services of the competent authorities (or those countries with which the EEA has a Mutual Recognition Agreement for their own territories) as certification that acceptable standards of GMP are in place at those non-community sites. The RMS considers that the pharmacovigilance system as described by the applicant fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country. The Marketing Authorisation Holder has provided adequate justification for not submitting a Risk Management Plan. 34

II. ABOUT THE PRODUCT Name of the product in the Reference Member State Name(s) of the active substance(s) (INN) Pharmacotherapeutic classification (ATC code) Neovent TM and Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension Salmeterol xinafoate Selective β 2 adrenoceptor agonists (R03AC12) Pharmaceutical form and strength(s) 25 micrograms per actuation pressurised inhalation, suspension Reference numbers for the Decentralised Procedure Reference Member State United Kingdom Member States concerned UK/H/3624/001/DC: Germany (DE), Ireland (IE), The Netherlands (NL) and Poland (PL) UK/H/3625/001/DC: Germany (DE) Marketing Authorisation Number(s) PL 08137/0272 and 5 Name and address of the authorisation holder Neolab Limited 57 High Street Odiham HANTS RG29 1LF U.K. 35

III SCIENTIFIC OVERVIEW AND DISCUSSION III.1 QUALITY ASPECTS S. Active substance Salmeterol Xinafoate INN/Ph.Eur name: Salmeterol Xinafoate Chemical name: (R,S) 4-Hydroxy-a'-[[[6-(-l-phenyl butoxyl)hexyl]amino]-methyl]-1,3, benzenedimethanol, 1-hydroxy-2-naphthoate Structural formula: Molecular formula: C 36 H 45 O 7 N Molecular weight: 603.7 Appearance: Solubility: A white to off white, crystalline powder Soluble in methanol, slightly soluble in ethanol and practically insoluble in water. Salmeterol xinafoate is the subject of a European Pharmacopoeia monograph. All aspects of the manufacture of the active substance from its starting materials are controlled by a Certificate of Suitability. Appropriate proof of structure data has been supplied for the active pharmaceutical ingredient. All potential known impurities have been identified and characterised. An appropriate specification is provided for the active substance, with suitable test methods and limits. Analytical methods have been appropriately validated and are satisfactory for ensuring compliance with the relevant specifications. Batch analysis data are provided and comply with the proposed specification. Satisfactory Certificates of Analysis have been provided for all reference standards used. Satisfactory specifications and Certificates of Analysis have been provided for all aspects of the container-closure system. A declaration has been provided that the primary packaging complies with current regulations concerning contact with foodstuff. Appropriate stability data have been generated showing the active substance to be a physically and chemically stable drug, and supporting an appropriate retest period. P. Medicinal Product Other Ingredients Other ingredients consist of pharmaceutical excipients anhydrous ethanol, soya lecithin (E322) and norflurane (HFA 134a). 36

Anhydrous ethanol complies with its European Pharmacopoeia monograph. Soya lecithin complies with the Unites States Pharmacopoeia. Norflurane (HFA 134a) complies with in-house specifications. None of the excipients used contain material of animal or human origin. No genetically modified organisms (GMO) have been used in the preparation of these products. Pharmaceutical Development The objective of the development programme was to produce salmeterol xinafoate containing products that could be considered generic medicinal products of Serevent Evohaler 25 micrograms per actuation pressurised inhalation suspension, first authorised in the UK to Glaxo Wellcome UK Limited on 12 th December 2005 (PL 10949/0369). The applicant has provided a suitable product development section. Justifications for the use and amounts of each excipient have been provided and are valid. Manufacturing Process A satisfactory batch formula has been provided for the manufacture of the product, along with an appropriate account of the manufacturing process. The manufacturing process has been validated and has shown satisfactory results. Process validation data on production-scale batches have been provided. The results are satisfactory. Finished Product Specification The finished product specification proposed for the product is acceptable. Test methods have been described and have been adequately validated, as appropriate. Batch data have been provided and comply with the release specification. Certificates of Analysis have been provided for any working standards used. Container-Closure System This product is packaged in a pressurised aluminium canister containing a white suspension sealed with a metering valve, with a mid-green polypropylene actuator and a pale green polypropylene dust cap. Each canister provides 120 actuations, each actuation containing 25 micrograms of salmeterol (as xinafoate) corresponding to a delivered dose (ex-actuator) of 21 micrograms salmeterol (as xinafoate). Satisfactory specifications and Certificates of Analysis have been provided for all packaging components. All primary product packaging complies with EU legislation regarding contact with food. Stability of the product Stability studies were performed on batches of the finished product in the packaging proposed for marketing and in accordance with current guidelines. These data support a shelf-life of 2 years. Storage instructions are Store above 30 C, Do not freeze and The canister contains a pressurised liquid. Do not expose to temperatures higher than 50ºC. Do not puncture, break or burn even when apparently empty. 37

Summary of Product Characteristics (SmPCs), Patient Information Leaflets (PILs), Labels The SmPCs, PILs and labelling are pharmaceutically acceptable. User testing results have been submitted for these products. The results indicate that the PILs are well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that they contain. MAA forms The MAA forms are pharmaceutically satisfactory. Expert report The pharmaceutical expert report has been written by an appropriately qualified person and is a suitable summary of the pharmaceutical dossier. Conclusion It is recommended that Marketing Authorisations are granted for these applications. 38

III.2 NON-CLINICAL ASPECTS The pharmacodynamics, pharmacokinetics and toxicological properties of salmeterol xinafoate are well-known. As salmeterol xinafoate is a widely used, well-known active substance, the applicant has not provided any additional studies and none are required. An overview based on a literature review is, thus, appropriate. The applicant has considered aspects that might give rise to altered toxicological properties specific to the proposed product, viz the inclusion of excipients not present in the reference product and the potential for toxicity from the leachates. The potential for toxicity from the potential leachate polybutylene terephthalate dimer was considered. It was concluded that this potential leachable will not pose any toxicological risk at the concentrations expected to occur in the product. The non-clinical expert report has been written by an appropriately qualified person and is a suitable summary of the non-clinical aspects of the dossier. The Marketing Authorisation Holder has provided adequate justification for not submitting an Environmental Risk Assessment. In conclusion there are no objections to the approval of these applications from a non-clinical perspective. 39

III.3 CLINICAL ASPECTS CLINICAL PHARMACOLOGY Four clinical pharmacology studies were submitted with these applications, three pharmacokinetic studies (one of which was a study using the Volumatic spacing device) and one pharmacodynamic study. Pharmacokinetics Study 1 A single-dose, open-label, two-treatment, two-way, two-period crossover study to compare the pharmacokinetics of 200mcg salmeterol administered from test (salmeterol xinafoate HFA pmdi 25mcg/actuation) and reference inhalers (Serevent Evohaler, A&H) in healthy male subjects who also received activated charcoal. Subjects were not allowed to drink water from 1 hour before until 1 hour after dosing. No food was permitted until 4 hours after dosing. Blood samples were taken pre- and up to 24 hours post dose. There was a washout period of 7 days between each treatment period. Pharmacokinetic parameters were measured from the plasma and statistically analysed. Results for salmeterol xinafoate are presented below as untransformed mean values: Treatment AUC 0-t (hr.pg/ml) AUC 0- (hr.pg/ml) C max (pg/ml) Test (T) 1230.16 1499.50 891.01 Reference (R) 1088.90 1281.85 807.07 T/R Ratio 113.06 116.98 110.40 (90% CI) 99.58 128.35 103.52 132.19 99.33 122.71 Study 2 A single-dose, open-label, two-treatment, two-way, two-period crossover study comparing 200mcg salmeterol administered from test (salmeterol xinafoate HFA pmdi 25mcg/actuation) and reference inhalers (Serevent Evohaler, A&H) in healthy male subjects. In this study charcoal was not administered to subjects, i.e., it was intended to evaluate drug absorption via both pulmonary and gastrointestinal routes. Subjects were not allowed to drink water from 1 hour before until 1 hour after dosing. No food was permitted until 4 hours after dosing. Blood samples were taken pre- and up to 24 hours post dose. There was a washout period of 7 days between each treatment period. Pharmacokinetic parameters were measured from the plasma and statistically analysed. 40

Results for salmeterol xinafoate are presented below as untransformed mean values: Treatment AUC 0-t (hr.pg/ml) AUC 0- (hr.pg/ml) C max (pg/ml) Test (T) 1502.27 1815.42 972.98 Reference (R) 1453.13 1742.17 880.01 T/R Ratio 103.38 104.20 110.56 (90% CI) 92.07 116.09 90.37 120.16 89.70 136.29 In each of these studies the results for the primary variables indicated that the 90% confidence intervals test/reference ratio of geometric means for AUC 0-t and C max for salmeterol xinafoate do not lie within acceptable limits (80-125%). Thus, bioequivalence has not been shown between the test and reference products in these studies. This does not necessarily preclude product approval as this is a hybrid application but suggests the need for additional clinical safety data. In addition to this, the applicant conducted a third pharmacokinetic study, in which test and referencce products were compared each in conjunction with a Volumatic spacing device. This study compared the test and reference products inhaled via a Volumatic spacing device using a deep breathing technique. This in vivo model was agreed given that, on the basis of previous pharmacokinetic and in vitro data, it was considered to be the model most likely to differentiate test and reference products. The Volumatic Spacing Device Study An open-label, randomised, two-treatment, two-period, two-sequence, single dose, crossover design. Twenty-four healthy adult male human subjects under fasting conditions were administered 100 mcg doses (4 x 25 mcg puffs) of T and R products. Subjects self administered 4 puffs via a Volumatic spacing device using a deep breathing technique; following a complete exhalation subjects inhaled deeply and slowly immediately post actuation and held their breath for at least for 10 seconds (or as long as was comfortable). The time interval between two consecutive puffs was approximately 60 seconds. Blood samples were taken pre- and up to 24 hours post-dose. 41

Results for salmeterol xinafoate are presented below as log-transformed values: Treatment AUC 0-t (hr.pg/ml) AUC 0- (hr.pg/ml) C max (pg/ml) Test (T) 1271.42 1540.89 1391.64 Reference (R) 1402.13 1727.01 1471.96 T/R Ratio 90.68 89.22 94.54 (90% CI) 83.87 98.03 82.15 96.91 87.11 102.61 The results for the primary variables indicated that the 90% confidence intervals test/reference ratio of geometric means for AUC 0-t and C max for salmeterol xinafoate lie within acceptable limits (80-125%). Thus, bioequivalence has been shown between the test and reference products in this study. Pharmacodynamics A single-centre randomised, double blind, placebo controlled, seven-way, seven-period crossover study to determine the systemic pharmacodynamic effects of Salmeterol xinafoate HFA pmdi compared with Serevent Evohaler in healthy adult male human subjects under fasted conditions. Subjects in this crossover study were randomised to one of 7 treatment sequences. Each sequence comprised 3 single doses of test, 3 single doses of reference and one single dose of placebo in a different order. The test product was salmeterol xinafoate HFA pmdi 25 μg/actuation. The following single doses of the test product were administered: Salmeterol xinafoate HFA pmdi 2 x 25 μg/actuation (50 μg) Salmeterol xinafoate HFA pmdi 6 x 25 μg/actuation (150 μg) Salmeterol xinafoate HFA pmdi 12 x 25 μg/actuation (300 μg) The reference product was Serevent Evohaler (containing Salmeterol xinafoate 25μg/actuation), (Allen and Hanburys, UK) The following single doses of the reference product were administered: Serevent Evohaler 2 x 25 μg/actuation (50 μg) Serevent Evohaler 6 x 25 μg/actuation (150 μg) Serevent Evohaler 12 x 25 μg/actuation (300 μg) Placebo inhalers corresponding to each of the active treatments were also administered to maintain blinding. The applicant has performed analyses of heart rate at 10 minutes, 20 minutes, serum potassium at 4 hours, QTc at 10 minutes and 20 minutes and blood glucose at 30 minutes vs. placebo. The results are shown in the following tables: 42

Comparison of all doses with placebo for heart rate at 10 and 20 minute timepoints: Comparison of all doses with placebo for serum potassium at 4hrs timepoint (Meq/L): 43

Comparison of all doses with placebo for QTc at 10 and 20 minute timepoints: Comparison of all doses with placebo for blood glucose at 30 minute timepoint: 44

Comparison between doses for heart rate at 10 and 20 minutes: Comparison between doses for serum potassium at 4 hours and blood glucose at 30 minutes (PP population): 45

Comparison between doses for QTc at 10 and 20 minutes (PP population): 46

Comparative analysis between treatment for Heart rate at 10 and 20 minutes, serum potassium at 4 hours, blood glucose at 30 minutes and QTc at 10 and 20 minutes for PP population: Comparative analysis between treatment for heart rate at 20minutes for Safety population: 47

Relative potency Analysis for Heart rate between doses 150mcg and 300mcg (PP population): Relative potency Analysis for Serum potassium between doses 150mcg and 300mcg (PP population): Relative potency results for blood glucose endpoint between doses 150mcg and 300mcg (PP population): 48

Equivalence has been shown between the test product and the reference product, based on the following observations:- The clinical mean values of the test product were not statistically different from the reference product for heart rate at 20min, AUC heart rate 0-4hrs, AUC heart rate 0-12hrs, maximum heart rate 0-12hrs, blood glucose at 30min and AUC blood glucose 0-4hrs; Relative potency was within the limits of 0.67 to 1.5 for heart rate at 20min, AUC heart rate 0-4hrs, AUC heart rate 0-12hrs, maximum heart rate 0-12hrs, blood glucose at 30min and AUC blood glucose 0-4hrs; Statistically significant dose response was evident between the lower dose of the test and reference product vs. placebo for heart rate at 20min, AUC heart rate 0-4hrs, AUC heart rate 0-12hrs, maximum heart rate 0-12hrs, blood glucose at 30min and AUC blood glucose 0-4hrs; Statistically significant dose response was evident between the lower dose of the test and reference product vs. placebo for heart rate at 20min, AUC heart rate 0-4hrs, AUC heart rate 0-12hrs, maximum heart rate 0-12hrs, blood glucose at 30min and AUC blood glucose 0-4hrs; Statistically significant dose response was evident between the supratherapeutic doses of the test and reference products vs. placebo for heart rate at 20min, AUC heart rate 0-4hrs, AUC heart rate 0-12hrs, maximum heart rate 0-12hrs, blood glucose at 30min and AUC blood glucose 0-4hrs; Statistically significant dose response was evident between all three doses of the test and reference products for heart rate at 20min, AUC heart rate 0-4hrs, AUC heart rate 0-12hrs, maximum heart rate 0-12hrs, blood glucose at 30min and AUC blood glucose 0-4hrs. The comparisons with placebo for heart rate, QTc interval, serum potassium and blood glucose show statistically significant differences between most dose levels and placebo. The results for the 50μg dose were not statistically significant for some of the endpoints. Of more interest are the comparisons provided between doses for these pharmacodynamic endpoints. The results provided show significant differences between doses for heart rate and blood glucose. For blood glucose the dose response starts around 150μg and for heart rate at 20 minutes the dose response starts around 50μg. The serum potassium and QTc interval endpoints are less useful as significant differences were not seen between adjacent doses. Therefore it is appropriate to present the results for the heart rate and blood glucose endpoints in terms of the relative potency of the test and reference products. For blood glucose a comparison of the 150 and 300μg doses is appropriate. For heart rate the relative potency across the 3 dose levels studied could be investigated. The applicant has investigated 5 parameters of heart rate. The relative potency analyses provided for heart rate provide good evidence of equivalence for this endpoint. It is only for heart rate at 10 minutes that the lower limit is marginally outside the arbitrary lower limit of 0.67 specified in the CHMP Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) including the Requirements for Demonstration of Therapeutic Equivalence Between Two Inhaled Products for Use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Adults and for Use in the Treatment of Asthma in Children and Adolescents CHMP/EWP/4151/00 Rev. 1 22 January 2009. 49

The relative potency results for blood glucose produce confidence intervals within the specified 0.67-1.5 limits. Looking at all the results provided by the applicant it is accepted that in this study blood glucose and heart rate are sensitive parameters to detect differences between test and reference products if they exist. The relative potency results for these endpoints provide good evidence of therapeutic equivalence between the test and reference products. CLINICAL EFFICACY Two clinical studies were submitted neither of which provided sufficient evidence of therapeutic equivalence due to lack of sensitivity in both studies. SAFETY With the exception of the data submitted during the studies, no new safety data were submitted with these applications and none were required. No new or unexpected safety concerns were raised during the studies. CHILDREN The applicant did not submit clinical data in support of the authorisation of salmeterol pressurised inhalation suspension in children. In the light of this lack of data in children these new formulations of salmeterol, Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension, can be authorised for use in adults and adolescents aged over 12 years only at this time. They CANNOT be authorised for use in children 12 years of age and younger. It was agreed that a Variation to the Marketing Authorisations would be submitted at the earliest opportunity post-authorisation in respect of the use of this long-acting β 2 agonist in children 12 years of age and younger. SUMMARY OF PRODUCT CHARACTERISTICS (SmPCS), PATIENT INFORMATION LEAFLETS (PILS) AND LABELLING The SmPCs, PILs and labelling are medically satisfactory and consistent with those for the reference products, where appropriate. CLINICAL EXPERT REPORT The clinical expert report has been written by an appropriately qualified physician and is a suitable summary of the clinical aspects of the dossier. MAA FORM The MAA Forms are medically satisfactory. CONCLUSIONS It is recommended that Marketing Authorisations are granted for these new formulations of salmeterol, Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension for use in adults and adolescents aged over 12 years with asthma and for use in adults with chronic obstructive pulmonary disease. 50

IV OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT QUALITY The important quality characteristics of Neovent TM /Sereflo TM CFC-free Inhaler 25 micrograms per actuation pressured inhalation, suspension are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance. NON-CLINICAL The pharmacodynamics, pharmacokinetics and toxicological properties of salmeterol xinafoate are well-known. As salmeterol xinafoate is a widely used, well-known active substance, the applicant has not provided any additional studies and none are required EFFICACY Two pharmacokinetic studies were submitted which demonstrated that the test and reference products were non-bioequivalent; slightly greater plasma exposure was observed with the test product. This finding was deemed not to preclude product approval if it could be shown that greater exposure to the test product does not adversely affect product safety. A third pharmacokinetic study was presented in which test and referencce products were compared, each administered via a Volumatic spacing device. This study demonstrated bioequivalence between test and reference products. One pharmacodynamic study was submitted. Although subject to certain design limitations which may have biased towards equivalence, such as assessment of efficacy parameters at pharmacologically irrational timepoints and over prolonged periods of time and the potential confounding influence of food intake, this study did suggest equivalence of pharmacodynamic effects between test and reference products. Two clinical studies were also submitted. However due to lack of assay sensitivity neither study provided sufficient evidence of therapeutic equivalence. SAFETY With the exception of the data submitted during the studies, no new safety data were submitted with these applications and none was required. No new or unexpected safety concerns were raised during the studies. CHILDREN The applicant has not submitted clinical data in support of the authorisation of salmeterol pressurised inhalation suspension in children. In the light of this lack of data in children these new formulations of salmeterol, Neovent TM /Sereflo TM CFC-free inhaler 25 micrograms per actuation pressurised inhalation, suspension, cannot be authorised for use in children 12 years of age and younger at this time. It has been agreed that a Variation to the Marketing Authorisations will be submitted at the earliest opportunity post-authorisation in respect of the use of this long-acting β 2 agonist in children 12 years of age and younger. 51

PRODUCT INFORMATION The SmPCs, PILs and labelling are satisfactory and consistent with product information for the reference product. RISK-BENEFIT ASSESSMENT The quality of the products is acceptable and no new non-clinical concerns have been identified. Clinically the only concern relates to use in children 12 years of age and younger and in the light of a lack of any data presented in this young age group marketing authorisations for use in children 12 years of age and younger cannot be granted at this time. Extensive clinical experience with salmeterol xinafoate is considered to have demonstrated the therapeutic value of the compound. The risk benefit for use of these new formulations of salmeterol in adults and adolescents aged over 12 years is considered to be positive. 52

Module 6 STEPS TAKEN AFTER INITIAL PROCEDURE - SUMMARY Date submitted Application type Scope Outcome 53